To include your compound in the COVID-19 Resource Center, submit it here.

Synergen Inc, Amgen Inc deal

Synergen, which said it was disappointed by Phase III data of its Antril anti-sepsis drug,

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE